Herbal medicines and perioperative care

JAMA

Volumn 286, Issue 2, 2001, Pages 208-216

  Ang Lee, Michael K ^a   Moss, Jonathan ^a   Yuan, Chun Su ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; KAVA; VALERIAN;

ALTERNATIVE MEDICINE; BLEEDING; CARDIOVASCULAR DISEASE; DATA BASE; DRUG SAFETY; ECHINACEA; EPHEDRA; GARLIC; GINSENG; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; HYPOGLYCEMIA; MEDICAL INFORMATION; PATIENT CARE; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; PHYTOTHERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0034945280     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.2.208     Document Type: Review

References (122)

1. Alternative medicine use in presurgical patients
2. Herbal medications: Current trends in anesthesiology practice-a hospital survey
3. Adverse drug interactions in anesthesia
4. NBJ herbal and botanical U.S. consumer sales
5. Glucosamine and chondroitin for treatment of osteoarthritis
6. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomized, placebo-controlled clinical trial
7. Trends in alternative medicine use in the United States, 1990-1997; results of a follow-up study
8. Unconventional medicine in the United States: Prevalence, costs, and patterns of use
9. American's views on the use and regulation of dietary supplements
10. Advising patients who seek alternative medical therapies
11. Use of alternative health care by family practice patients
12. Growing use of medicinal botanicals forces assessment by drug regulators
13. Medicinal herbs in the United States: Research needs
14. Herbs as medicines
15. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions
16. Herbal roulette
17. Harmless herbs? a review of the recent literature
18. Contamination of botanical dietary supplements by Digitalis lanata
19. Cancer and herbs
20. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)
21. Adulterants in Asian patent medicines
22. Safer use of traditional remedies: Remedies may contain cocktail of active drugs
23. Arsenic and mercury in traditional Chinese herbal balls
24. Herbal quality seems to be growing
25. Phytomedicine research in Germany
26. Label's potency claims often inaccurate, analysis finds
27. Complementary medicine
28. Herb-drug interactions
29. Herb-drug interactions
30. Monitoring the safety of herbal medicine: WHO project is under way
31. Herbal Rx - The promises and pitfalls
32. Toxic effects of herbal medications and food supplements
33. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: Face-to-face Interviews with 515 users of herbal remedies
34. Echinacea for preventing and treating the common cold
35. Echinacea
36. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients
37. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis
38. Echinacea
39. Safety issues with herbal medicine
40. Echinacea-associated anaphylaxis
41. Content versus label claims in ephedra-containing dietary supplements
42. From the Food and Drug Administration
43. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids
44. Anesthetic implications of concurrent diseases
45. Hypersensitivity myocarditis associated with ephedra use
46. Ephedrine nephrolithiasis associated with chronic ephedrine abuse
47. Ma-huang strikes again: Ephedrine nephrolithiasis
48. Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults
49. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang)
50. Garlic for treating hypercholesterolemia: A meta-analysis of randomized clinical trials
51. Evidence for the mechanism by which garlic inhibits platelet aggregation
52. Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets
53. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: A case report
54. Analysis of responses of garlic derivatives in the pulmonary valscular bed of the rat
55. Effect of allicin from garlic powder on serum lipids and blood pressure in rats fed with a high cholesterol diet
56. A meta-analysis of the effect of garlic on blood pressure
57. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia: North American EGb Study Group
58. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease
59. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers
60. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761
61. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761)
62. Effect of a ginkgolide mixture (BN 52063) in antagonizing skin and platelet responses to platelet activating factor in man
63. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion
64. Subarachnoid haemorrhage associated with Ginkgo biloba
65. Ginkgo biloba
66. Association of Ginkgo biloba with intracerebral hemorrhage
67. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract
68. Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy
69. Solid-phase extraction and gas chromatography - Mass spectrometry determination of kaempferol and quercetin in human urine after consumption of Ginkgo biloba tablets
70. Ginkgo
71. New substances of plant origin which increase nonspecific resistance
72. Ginseng pharmacology: Multiple constituents and multiple actions
73. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus
74. Effects of various ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets
75. Antiplatelet components in Panax ginseng
76. Effects of dietary supplementation of lipophilic fraction from Panax ginseng on cGMP and cAMP in rat platelets and on blood coagulation
77. Antiplatelet actions of panaxynol and ginsenosides isolated from ginseng
78. Probable interaction between warfarin and ginseng
79. American ginseng: III, pharmacokinetics of ginsenosides in the rabbit
80. Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis
81. Kava: Piper methysticum
82. Pharmacology of kava.1
83. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents
84. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum)
85. Coma from the health food store: Interaction between kava and alprazolam
86. Kava dermopathy
87. Metabolism of some kava pyrones in the rat
88. St John's wort for depression: A systematic review
89. Effectiveness of St John's wort in major depression
90. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract
91. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes
92. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers
93. St. John's wort and antidepressant drug interactions in the elderly
94. Acute St. John's wort toxicity
95. Inhibition of monoamine oxidase by hypericin
96. Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain
97. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity
98. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression
99. Second thoughts about safety of St. John's wort
100. Indinavir concentrations and St. John's wort
101. Safety of St. John's wort
102. Drug interaction of St. John's wort with cyclosporin
103. Acute heart transplant rejection due to Saint John's wort
104. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum)
105. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin
106. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers
107. The scientific basis for the reputed activity of valerian
108. Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis
109. 3H]GABA release
110. Synaptosomal GABA release as influenced by valerian root extract - Involvement of the GABA carrier
111. Characterization of the central nervous depressant activity of a commercially available valerian root extract
112. Cardiac complications and delirium associated with valerian root withdrawal
113. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination
114. The use of medicinal herbs by human immunodeficiency virus-infected patients
115. Advising patients about herbal therapies
116. Alternative therapies for the treatment of childhood cancer
117. Herbal medicines: What do we need to know?
118. Polypharmacy in a general surgical unit and consequences of drug withdrawal
119. Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: Randomized controlled trial